Sandoz has confirmed the launch of its Hyrimoz biosimilar rival to Humira in Canada, with other biosimilars firms having also set their sights on a mid-February launch.

Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.

Sandoz Canada is looking to roll out its biosimilar to AbbVie’s Humira early in the new year following approval from Health Canada, with multiple other adalimumab candidates also reportedly approved.

The Indian clinical research segment has managed to retain some buoyancy despite pandemic-related disruptions, with an estimated 70 global trials cleared to October by the regulator. But audiovisual recording of the informed consent process has been particularly challenging in the case of subjects in isolation wards.